[1]李 堃,葛 飞,孙茂秋,等.健肝散体外对拉米夫定耐药株病毒表达抑制及增敏作用的研究[J].陕西中医,2023,(9):1188-1192.[doi:DOI:10.3969/j.issn.1000-7369.2023.09.006]
　LI Kun,GE Fei,SUN Maoqiu,et al.Study on the inhibitory and sensitizing effect of Jiangan powder on the expression of LMV resistant strain virus in vitro[J].,2023,(9):1188-1192.[doi:DOI:10.3969/j.issn.1000-7369.2023.09.006]
点击复制

健肝散体外对拉米夫定耐药株病毒表达抑制及增敏作用的研究
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2023年9期
页码:
1188-1192
栏目:
基础研究
出版日期:
2023-09-05

文章信息/Info

Title:
Study on the inhibitory and sensitizing effect of Jiangan powder on the expression of LMV resistant strain virus in vitro
作者:
李 堃1; 2; 葛 飞1; 孙茂秋1; 严展鹏2; 仲 婕1; 季 瑜1; 朱方石2
(1.海安市中医院脾胃病科,江苏 海安 226600; 2.江苏省中医药研究院中西医结合临床研究室,江苏 南京 210046)
Author(s):
LI Kun; GE Fei; SUN Maoqiu; YAN Zhanpeng; ZHONG Jie; JI Yu; ZHU Fangshi
(Department of Spleen and Stomach Diseases,Haian Hospital of Traditional Chinese Medicine,Haian 226600,China)
关键词:
乙肝;  健肝散;  拉米夫定;  耐药;  增敏;  细胞实验;  HepG2.2.15;  抗病毒作用
Keywords:
Hepatitis B;  Jiangan powder;  Lamivudine;  Drug resistance;  Sensitization;  Cell experiment;  HepG2.2.15;  Antiviral effect
分类号:
R 512.62
DOI:
DOI:10.3969/j.issn.1000-7369.2023.09.006
文献标志码:
A
摘要:
目的:探讨健肝散(JGP)对HepG2.2.15耐药株对拉米夫定(LMV)耐药的影响。方法:利用药物浓度递增冲击的方法,建立HepG2.2.15/LMV耐药细胞株模型,CCK8法检测耐药株、敏感株IC50值,观察健肝散(JGP)含药血清对耐药株IC50值影响; 设置HepG2.2.15耐药株+正常大鼠血清组及HepG2.2.15耐药株+JGP含药血清组,荧光定量PCR检测两组细胞HBV-pgRNA表达水平,提取RNA后ELISA检测两组细胞上清HBsAg和HBeAg的表达水平。结果:①与HepG2.2.15细胞耐药株+正常大鼠血清组相比,HepG2.2.15细胞耐药株+JGP含药血清的IC50值显著降低; ②与耐药细胞株+正常血清组相比,健肝散含药血清可抑制HepG2.2.15 LMV耐药细胞株HBV-pgRNA的表达,差异有统计学意义(P<0.01); ③与HepG2.2.15/LMV耐药细胞株添加正常血清组相比,JGP含药血清可抑制HepG2.2.15/LMV耐药细胞株HBsAg和HBeAg的表达,差异具有统计学意义(P<0.01)。结论:JGP体外可以增加耐药株对LMV敏感性,有效降低耐药株HBV的表达,对LMV耐药具有一定缓解作用。
Abstract:
Objective:To investigate the effect of Jiangan powder(JGP)on lamivudine(LMV)resistance in HepG2.2.15 resistant strains.Methods:The drug resistant cell line model of HepG2.2.15/LMV was established by the method of increasing drug concentration.The IC50 values of drug resistant and sensitive strains were detected by CCK8 method,and the effect of JGP containing serum on the IC50 value of drug resistant strains was observed.The HepG2.2.15 resistant strain + normal rat serum group and the HepG2.2.15 drug resistant strain + JGP drug containing serum group were set.The expression level of HBV-pgRNA in the cells of the two groups was detected by fluorescence quantitative PCR,and the expression levels of HBsAg and HBeAg in the supernatant of the two groups were detected by ELISA after RNA extraction.Results:①Compared with the drug-resistant HepG2.2.15 cell line + normal rat serum group,the IC50 value of the drug-containing serum of the drug-resistant HepG2.2.15 cell line + JGP decreased significantly.②Compared with the drug-resistant cell line + normal serum group,the drug-containing serum of Jiangan powder could inhibit the expression of HBV-pgRNA in HepG2.2.15 LMV drug-resistant cell line(P< 0.01).③Compared with the group of HepG2.2.15/LMV drug-resistant cell line supplemented with normal serum,JGP could inhibit the expression of HBsAg and HBeAg of HepG2.2.15/LMV drug-resistant cell line,and there was significant difference.Conclusion:JGP can increase the sensitivity of drug-resistant strains to LMV in vitro,effectively reduce the expression of HBV in drug-resistant strains,and alleviate the drug resistance of hepatitis B lamivudine(LMV)to a certain extent.

参考文献/References:

[1] 杨丽娟,郝小康,周 军.慢性乙型肝炎患者Toll样受体2与乙型肝炎病毒DNA表达水平相关性研究[J].陕西医学杂志,2021,50(6):697-700.
[2] 代海峰,季 瑜.健肝散联合拉米夫定治疗慢性乙肝104例及其对YMDD变异的影响[J].中国中西医结合消化杂志,2014,22(10):588-590.
[3] 骆抗先.乙型肝炎基础与临床[M].北京:人民卫生出版社,2012:301-302.
[4] 周 培,渠淑云.核苷(酸)类似物治疗慢性乙型肝炎患者病毒耐药位点研究现状[J].中西医结合肝病杂志,2020,30(2):188-192.
[5] 张怡青,常静霞,王 洁,等.慢性乙型肝炎患者核苷(酸)类似物耐药位点多变性分析[J].中国肝脏病杂志:电子版,2015,7(3):70-73.
[6] 段淑红,苑晓冬,刘晓燕,等.持续及间断应用拉米夫定或恩替卡韦治疗慢性乙型肝炎出现病毒耐药变异概率的临床观察[J].中华肝脏病杂志,2018,26(9):646-649.
[7] 杨庆华.新型核苷衍生物的设计、合成及抗HBV活性研究[D].郑州:郑州大学,2015.
[8] 王雪艳.一种新型化合物抑制乙肝病毒复制及阿德福韦耐药变异株对其敏感性的研究[D].北京:中国疾病预防控制中心,2010.
[9] 崔璐璐,聂俊军.慢肝康丸配合西药治疗急性乙型肝炎及对病毒复制的影响[J].陕西中医,2015,36(4):461-464.
[10] 陈寅萤,王 忠.中医药治疗慢性乙型肝炎的研究进展[J].世界中西医结合杂志,2020,15(4):779-784.
[11] 史艳平,陈 涛,李 丹,等.氧化苦参碱药理作用研究进展[J].陕西医学杂志,2018,47(2):271-273.
[12] Sang X,Wang R,Han Y,et al.T cell-associated immunoregulation and antiviral effect of oxymatrine in hydrodynamic injection HBV mouse model[J].Acta Pharmaceutica Sinica B,2017,7(3):311-318.
[13] 伍 磊,张志鹏.中药抗乙肝病毒活性及作用机制的研究进展[J].中草药,2020,51(24):6367-6376.
[14] Jang E,Kim BJ,Lee KT,et al.A survey of therapeutic effects of artemisia capillaris in liver diseases[J].Evid Based Complement Alternat Med,2015,2015:728137.
[15] 段树鹏,朱利红,李 鹏,等.丹参素靶向乙肝病毒逆转录酶抗乙肝及抗原表达影响机制研究[J].中国中药杂志,2016,41(7):1297-1301.
[16] Wang T,Jin W,Huang Q,et al.Clinical efficacy and safety of eight traditional chinese medicine combined with entecavir in the treatment of chronic hepatitis B liver fibrosis in adults:A network meta-analysis[J].Evid Based Complement Alternat Med,2020,2020:7603410.
[17] Pan Y,Ke Z,Ye H,et al.Saikosaponin C exerts anti-HBV effects by attenuating HNF1α and HNF4α expression to suppress HBV pgRNA synthesis[J].Inflamm Res,2019,68(12):1025-1034.
[18] Ashour ML,Wink M.Genus Bupleurum:A review of its phytochemistry,pharmacology and modes of actio[J].J Pharm Pharmacol,2011,63(3):305-321.
[19] Shen S,Xie Z,Cai D,et al.Biogenesis and molecular characteristics of serum hepatitis B virus RNA[J].PLoS Pathog,2020,16(10):e1008945.
[20] 李解军,冯 煦,常瑞霞.HBsAg、cccDNA和pgRNA水平检测在慢性乙型肝炎诊治中的价值[J].保健医学研究与实践,2021,18(4):95-98,102.

备注/Memo

备注/Memo:
基金项目:江苏省自然科学基金资助面上项目(BK20181235); 江苏省卫生健康委医学研究面上项目(M2022024); 江苏省南通市科技计划指导性项目(MSZ20192); 江苏省南通市卫生健康委员会科研立项课题(QA2020048)
更新日期/Last Update: 2023-09-08